Advertisement
Australia markets closed
  • ALL ORDS

    7,973.40
    -66.50 (-0.83%)
     
  • AUD/USD

    0.6645
    +0.0001 (+0.02%)
     
  • ASX 200

    7,732.40
    -63.60 (-0.82%)
     
  • OIL

    80.65
    -0.08 (-0.10%)
     
  • GOLD

    2,336.00
    +4.80 (+0.21%)
     
  • Bitcoin AUD

    93,741.40
    -3,155.91 (-3.26%)
     
  • CMC Crypto 200

    1,284.90
    -24.82 (-1.90%)
     

Inspire Medical Systems, Inc. to Report First Quarter 2023 Financial Results on May 2, 2023

Inspire Medical Systems
Inspire Medical Systems

MINNEAPOLIS, April 04, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the first quarter 2023 after the close of trading on Tuesday, May 2. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q1 2023 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Inspire's Q1 2023 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

ADVERTISEMENT

Following the call, a replay will be available on the Company's Investor Relations website approximately two hours after the event and archived on the site for two weeks.

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443